{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-23-000056","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.011005+00:00","generated_at":"2026-06-12T21:29:55.992706+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neurocrine Q2 beats with INGREZZA $440M (+26% YoY); raises 2023 sales forecast to $1.77-1.82B","bullets":["Q2 total revenue $452.7M vs $378.2M YoY; GAAP EPS $0.95 vs loss of $0.18, non-GAAP EPS $1.25 vs $0.84.","INGREZZA net product sales $440M (26% YoY); record new patient starts in Q2.","2023 INGREZZA guidance raised to $1.77-1.82B from prior range; reaffirms R&D and SG&A expense guidance.","Cash, cash equivalents and marketable securities $1.32B at June 30, 2023; up from $1.29B at year-end 2022.","PDUFA date for valbenazine in Huntington's chorea set for Aug 20, 2023; four Phase 2/3 readouts expected in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-23-000056","json":"https://secwatch.observer/filing/0000914475-23-000056.json","markdown":"https://secwatch.observer/filing/0000914475-23-000056.md","text":"https://secwatch.observer/filing/0000914475-23-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000056/0000914475-23-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000056/nbix-20230801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:29:55.992706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}